Barinthus Biotherapeutics (VACC) Stock Forecast, Price Target & Predictions
VACC Stock Forecast
Barinthus Biotherapeutics stock forecast is as follows:
Barinthus Biotherapeutics Financial Forecast
Barinthus Biotherapeutics Revenue Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Mar 22 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $334.00K | $468.00K | $6.17M | $15.02M | $35.00K |
| Avg Forecast | $751.50K | $668.00K | $584.50K | $620.00K | $620.00K | $250.00K | $600.00K | $3.31M | $3.57M | $35.00K |
| High Forecast | $1.37M | $1.22M | $1.07M | $1.13M | $1.13M | $455.64K | $1.09M | $6.03M | $6.51M | $63.79K |
| Low Forecast | $121.21K | $107.74K | $94.27K | $100.00K | $100.00K | $40.32K | $96.77K | $533.87K | $575.81K | $5.64K |
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | - | - | 1 |
| Surprise % | - | - | - | - | - | 1.34% | 0.78% | 1.86% | 4.21% | 1.00% |
Barinthus Biotherapeutics's average Quarter revenue forecast for Sep 23 based on 2 analysts is $620.00K, with a low forecast of $100.00K, and a high forecast of $1.13M. VACC's average Quarter revenue forecast represents a 85.63% increase compared to the company's last Quarter revenue of $334.00K (Jun 23).
Barinthus Biotherapeutics EBITDA Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Mar 22 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | - | - | 1 |
| EBITDA | - | - | - | - | $-16.11M | $-26.34M | $-18.74M | $8.33M | $2.75M | $-15.81M |
| Avg Forecast | $-184.22K | $-163.75K | $-143.28K | $-151.99K | $-151.99K | $-61.28K | $-147.08K | $-811.41K | $-875.15K | $-18.81M |
| High Forecast | $-335.76K | $-298.45K | $-261.15K | $-277.01K | $-277.01K | $-111.70K | $-268.07K | $-1.48M | $-1.60M | $-15.05M |
| Low Forecast | $-29.71K | $-26.41K | $-23.11K | $-24.51K | $-24.51K | $-9.88K | $-23.72K | $-130.87K | $-141.15K | $-22.58M |
| Surprise % | - | - | - | - | 105.96% | 429.75% | 127.40% | -10.27% | -3.14% | 0.84% |
1 analysts predict VACC's average Quarter EBITDA for Mar 23 to be $-147.08K, with a high of $-268.07K and a low of $-23.72K. This is -101.76% lower than Barinthus Biotherapeutics's previous annual EBITDA (Sep 22) of $8.33M.
Barinthus Biotherapeutics Net Income Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Mar 22 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | - | - | 1 |
| Net Income | - | - | - | - | $-14.07M | $-23.80M | $-18.22M | $8.24M | $2.60M | $-15.93M |
| Avg Forecast | $59.20M | $51.57M | $60.55M | $-27.27M | $-26.89M | $-22.66M | $-22.28M | $12.67M | $11.91M | $-18.95M |
| High Forecast | $46.97M | $40.91M | $48.04M | $-20.74M | $-20.74M | $-17.98M | $-17.67M | $10.06M | $9.45M | $-15.16M |
| Low Forecast | $61.65M | $53.70M | $63.05M | $-27.27M | $-26.89M | $-23.60M | $-23.20M | $13.20M | $12.40M | $-22.74M |
| Surprise % | - | - | - | - | 0.52% | 1.05% | 0.82% | 0.65% | 0.22% | 0.84% |
Barinthus Biotherapeutics's average Quarter net income forecast for Mar 23 is $-22.28M, with a range of $-23.20M to $-17.67M. VACC's average Quarter net income forecast represents a -370.28% decrease compared to the company's last Quarter net income of $8.24M (Sep 22).
Barinthus Biotherapeutics SG&A Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Mar 22 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | - | - | 1 |
| SG&A | - | - | - | - | $961.00K | $13.13M | $12.14M | $-11.13M | $3.66M | $12.37M |
| Avg Forecast | $590.50K | $524.89K | $459.27K | $487.17K | $487.17K | $196.44K | $471.45K | $2.60M | $2.81M | $27.50K |
| High Forecast | $1.08M | $956.65K | $837.07K | $887.91K | $887.91K | $358.03K | $859.26K | $4.74M | $5.11M | $50.12K |
| Low Forecast | $95.24K | $84.66K | $74.08K | $78.58K | $78.58K | $31.68K | $76.04K | $419.49K | $452.44K | $4.43K |
| Surprise % | - | - | - | - | 1.97% | 66.83% | 25.75% | -4.28% | 1.31% | 449.84% |
Barinthus Biotherapeutics's average Quarter SG&A projection for Dec 23 is $487.17K, based on 2 Wall Street analysts, with a range of $78.58K to $887.91K. The forecast indicates a -49.31% fall compared to VACC last annual SG&A of $961.00K (Sep 23).
Barinthus Biotherapeutics EPS Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Mar 22 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | - | - | 1 |
| EPS | - | - | - | - | $-365.19 | $-0.00 | $-0.48 | $0.22 | $0.07 | $-0.64 |
| Avg Forecast | $1.54 | $1.34 | $1.58 | $-0.71 | $-0.70 | $-0.59 | $-0.58 | $0.33 | $0.31 | $0.74 |
| High Forecast | $1.22 | $1.07 | $1.25 | $-0.54 | $-0.54 | $-0.47 | $-0.46 | $0.26 | $0.25 | $0.59 |
| Low Forecast | $1.61 | $1.40 | $1.64 | $-0.71 | $-0.70 | $-0.61 | $-0.60 | $0.34 | $0.32 | $0.77 |
| Surprise % | - | - | - | - | 521.70% | 0.00% | 0.83% | 0.67% | 0.23% | -0.86% |
According to 1 Wall Street analysts, Barinthus Biotherapeutics's projected average Quarter EPS for Mar 23 is $-0.58, with a low estimate of $-0.60 and a high estimate of $-0.46. This represents a -363.64% decrease compared to VACC previous annual EPS of $0.22 (Sep 22).
Barinthus Biotherapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ACET | Adicet Bio | $1.26 | $32.50 | 2479.37% | Buy |
| SPRO | Spero Therapeutics | $1.29 | $10.00 | 675.19% | Buy |
| VOR | Vor Biopharma | $0.78 | $6.00 | 669.23% | Buy |
| CTMX | CytomX Therapeutics | $1.01 | $5.77 | 471.29% | Buy |
| MOLN | Molecular Partners | $6.06 | $29.00 | 378.55% | Buy |
| VACC | Barinthus Biotherapeutics | $5.00 | $22.00 | 340.00% | - |
| ANEB | Anebulo Pharmaceuticals | $1.89 | $6.00 | 217.46% | Buy |
| TIL | Instil Bio | $27.63 | $78.25 | 183.21% | Hold |
| STOK | Stoke Therapeutics | $13.10 | $30.60 | 133.59% | Buy |
| CCCC | C4 Therapeutics | $6.45 | $13.50 | 109.30% | Buy |
| ASMB | Assembly Biosciences | $16.98 | $35.50 | 109.07% | Buy |
| CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
| ACHL | Achilles Therapeutics | $1.03 | $2.00 | 94.17% | Buy |
| TYRA | Tyra Biosciences | $16.42 | $30.50 | 85.75% | Buy |
| DSGN | Design Therapeutics | $5.32 | $9.67 | 81.77% | Buy |
| THRD | Third Harmonic Bio | $12.11 | $16.15 | 33.36% | Buy |
| EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
| GRPH | LENZ Therapeutics | $3.18 | $4.00 | 25.79% | Hold |
| RVMD | Revolution Medicines, Inc. Warrant | $55.87 | $58.57 | 4.83% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
VACC Forecast FAQ
What are Barinthus Biotherapeutics's analysts' financial forecasts?
VACC's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $2.09M (high $3.81M, low $337.1K), average EBITDA is $-512K (high $-934K, low $-82.635K), average net income is $-99.092M (high $-77.133M, low $-101M), average SG&A $1.64M (high $2.99M, low $264.87K), and average EPS is $-2.58 (high $-2.008, low $-2.628).
Did the VACC's actual financial results beat the analysts' financial forecasts?
In terms of the last quarterly report (Jun 2023), Barinthus Biotherapeutics's revenue was $334K, beating the average analysts' forecast of $250K by 33.60%. The company's EBITDA was $-26.337M, beating the average prediction of $-61.285K by 42874.63%. Barinthus Biotherapeutics's net income was $-23.802M, beating the average estimation of $-22.661M by 5.04%. The company's SG&A was $13.13M, beating the average forecast of $196.44K by 6582.99%. Lastly, the company's EPS was $-0.0006, missing the average prediction of $-0.59 by -99.90%